November 14, 2023
Elite Diagnostic Limited (ELITE) for the first quarter ended September 30, 2023 reported a 4% increase in income totalling $196.23 million compared to $187.95 million in the corresponding first quarter last year.
Direct Cost amounted to $58.19 million (2022: $53.19 million), this represents an increase of 9% year over year. Consequently, gross profit increased by 2% to $138.04 million compared to $134.75 million for the first quarter ended September 30, 2022.
Admin Expense increased by 10% to close at $87.98 million (2022: $79.76 million), while Depreciation & Amortization increased by 7% from $38.96 million in 2022 to $41.67 million for the first quarter. As a result, Operating Profit for the first quarter amounted to $8.39 million, a 48% decrease relative to $16.03 million reported in 2022.
Foreign Loss for the first quarter amounted to $291,010, a 87% decrease relative to a loss of $2.23 million reported in 2022. Finance Cost totalled $13.61 million a 70% increase from the corresponding period last year. (2022: $8.01 million).
Loss Before Tax for the first quarter ended September 30, 2023, amounted to $5.48 million, relative to profit before tax of $5.81 million reported in 2022.
There was no Income Tax for the first quarter. Net Loss for the first quarter amounted to $5.48 million, relative to profit before tax of $5.81 million reported in 2022.
Consequently, Loss Per Share for the first quarter amounted to $0.02 (2022: EPS of $0.02). The twelve month trailing EPS was $0.01 and the number of shares used in these calculations was 353,400,000. Notably, ELITE’s stock price closed the trading period on November 13, 2023 at a price of $1.70 with a corresponding P/E ratio of 292.61x.
Elite noted “ The Drax Hall MRI unit, which was out of service for several months during the latter part of the previous financial year was brought back into service half-way through the quarter in late August, at which time all our revenue-generating equipment was fully functional for the first time in many quarters.”
Balance Sheet Highlights
As at September 30, 2023, total assets amounted to $1.08 billion, compared to $1.02 billion for last year. This increase in total assets was mainly as a result of an increase in ‘Receivables’ from $75.52 million in 2022 to $110.79 million as at September 2023.
Shareholder’s equity was $479.34 million (2022: $484.36 million), representing a book value per share of $1.36 (2022: $1.37).
Disclaimer:
Analyst Certification -The views expressed in this research report accurately reflect the personal views of Mayberry Investments Limited Research Department about those issuer (s) or securities as at the date of this report. Each research analyst (s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view (s) expressed by that research analyst in this research report.
Company Disclosure -The information contained herein has been obtained from sources believed to be reliable, however its accuracy and completeness cannot be guaranteed. You are hereby notified that any disclosure, copying, distribution or taking any action in reliance on the contents of this information is strictly prohibited and may be unlawful. Mayberry may effect transactions or have positions in securities mentioned herein. In addition, employees of Mayberry may have positions and effect transactions in the securities mentioned herein.
